Stock Code: 000028/200028 Notice No.: 2022-36

Short Form of the Stock: Sinopharm Accord /Accord B

China National Accord Medicines Corporation Ltd.Summary of Semi-Annual Report 2022

I. Important Notice

The summary of semi-annual report is excerpted from the full text of the semi-annual report. For the details investors should

carefully read the full text of the semi-annual report published on Juchao Information website (www.cninfo.com.cn) and Shenzhen

Stock Exchange Website etc. appointed by CSRC.All directors are attended the Board Meeting for report deliberation.Prompt of modified auditing opinion

□ Applicable √ Not applicable

Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting

period

□ Applicable √ Not applicable

The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reserves

Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period

□ Applicable √ Not applicable

II. Basic information of the company

1. Company profile

Short form of the stock Sinopharm Accord Accord B Stock code 000028 200028

Stock exchange for listing Shenzhen Stock Exchange

Person/Way to contact Secretary of the Board Rep. of security affairs

Name Chen Changbing Wang Zhaoyu

Accord Pharm. Bldg. No. 15 Ba Gua Si Accord Pharm. Bldg. No. 15 Ba Gua Si

Office add. Road Futian District Shenzhen Guangdong Road Futian District Shenzhen Guangdong

Province Province

Tel. +(86)755 25875222 +(86)755 25875222

E-mail gyyzinvestor@sinopharm.com gyyz0028@sinopharm.com

2. Main financial data and index

Whether it has retroactive adjustment or re-statement on previous accounting data

1□ Yes √ No

Increase/decrease in this

Current Period Same period of last year

report y-o-y

Operating revenue (RMB) 36128910049.98 33163091887.39 8.94%

Net profit attributable to shareholders of

674215912.93741445013.25-9.07%

the listed Company (RMB)

Net profit attributable to shareholders of

the listed Company after deducting non- 652857302.76 720954408.22 -9.45%

recurring gains and losses (RMB)

Net cash flow arising from operating

1041664059.171229373283.57-15.27%

activities (RMB)

Basic earnings per share (RMB/Share)

1.571.73-9.25%

(note 1)

Diluted earnings per share (RMB/Share) 1.57 1.73 -9.25%

Weighted average ROE 4.44% 5.22% 0.78percentage points down

Increase/decrease in this

End of current period End of last period report-end over that of last

period-end (+-)

Total assets (RMB) 45968980824.57 42783682431.81 7.45%

Net assets attributable to shareholder of

15342295205.2414924938052.502.80%

listed Company (RMB)

3. Number of shareholders and share-holding

Unit: share

Total preference shareholders

Total common shareholders at with voting rights recovered at

436890

period-end end of reporting period (if

applicable)

Top ten shareholders

Information of shares

Full name of Nature of Proportion of Amount of

Amount of restricted shares held pledged tagged or frozen

Shareholders shareholder shares held shares held

State of share Amount

Sinopharm State-owned

56.06%2399999915505770

Group Co. Ltd. Corporation

FIRST

SENTIER

INVESTORS

GLOBAL

Foreign

UMBRELLA 2.52% 10802495

Corporation

FUND PLC -

FSSA CHINA

GROWTH

FUND

2Hong Kong

Securities Foreign

1.73%7415259

Clearing Corporation

Company Ltd

China National

Pharmaceutical State-owned

1.24%5323043

Foreign Trade Corporation

Corp.National Social Domestic non

Security Fund state-owned 1.19% 5100032

413 Portfolio Corporation

BBH BOS S/A

FIDELITY FD - Foreign

0.78%3358761

CHINA FOCUS Corporation

FD

Fidelity

Investment

Domestic non

Management

state-owned 0.54% 2301737

(Hong Kong)

Corporation

Limited -

Client’s fund

CPIC Fund -

China Pacific

Life Insurance

Co. Ltd. - with-

profit insurance-

CPIC Fund

Domestic non

China Pacific

state-owned 0.47% 1999227

Life Equity

Corporation

Relative Income

(Guaranteed

Dividend)

single assets

management

plan

ICBC-Guolian

Andesheng

Domestic non

Small Selected

state-owned 0.38% 1632000

Securities

Corporation

Investment

Fund

UBS AG

Foreign

LONDON 0.30% 1271030

Corporation

BRANCH

3Sinopharm Group Co. Ltd. and China National Pharmaceutical Foreign Trade Corporation have

Explanation on associated the same actual controller which is China National Pharmaceutical Group Corporation. It is

relationship among the aforesaid unknown that there exists no associated relationship or belongs to the consistent actionist among

shareholders the other tradable shareholders regulated by the Management Measure of Information Disclosure

on Change of Shareholding for Listed Companies.

4. Changes of controlling shareholders or actual controller

Changes of controlling shareholders in reporting period

□ Applicable √ Not applicable

Changes of controlling shareholders had no change in reporting period.Changes of actual controller in reporting period

□ Applicable √ Not applicable

Changes of actual controller had no change in reporting period.

5. Total preferred stock shareholders of the Company and shares held by top ten shareholders with

preferred stock held

The Company had no shareholders with preferred stock held in the reporting.

6. Bonds in existence as of the approval date of the semi-annual report

□ Applicable √ Not applicable

III. Important events

On December 29 2021 Sinopharm Holding Guoda Drugstore Co. Ltd. (hereinafter referred to as "Guoda Drugstore") a

controlling subsidiary of the Company entered in to the Letter of Intent for Cooperation on the acquisition of some social retail

pharmacy assets of the Company's controlling shareholders with Sinopharm Holding Hubei Co. Ltd. (hereinafter referred to as

"Sinopharm Holding Hubei"). For details please refer to the Sinopharm Accord: Announcement on Related Transactions of

Controlling Shareholders' Fulfillment of Commitments and Solving the Problem of Horizontal Competition in Social Retail

Pharmacy Assets" (Announcement No.:2021-42) disclosed on www.cninfo.com.cn dated December 31 2021 .On June 27 2022 the seventh meeting of the ninth board of directors of the company reviewed and approved the Proposal on

Sinopharm Holding Guoda Drugstore Co. Ltd. Entrusting 100% Equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co.Ltd. and Changing the Way to Solve the Horizontal Competition of Social Retail Pharmacy Assets. The board of directors agreed

that Guoda Drugstore and Sinopharm Holding Hubei sign the Equity Escrow Agreement changing the original method of solving

the horizontal competition of social retail pharmacy assets from acquisition to escrow that is from Guoda Drugstore purchasing

51% equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co. Ltd. to escrowing 100% of its equity. On June 27 2022 the

4two parties formally signed the Equity Escrow Agreement. For details please refer to the Sinopharm Accord: Progress

Announcement on the Controlling Shareholder's Fulfillment of Commitments and Solving the Problem of Horizontal Competition

in Social Retail Pharmacy Assets" (Announcement No.:2022-28) disclosed on www.cninfo.com.cn dated June 29 2022.China National Accord Medicines Corporation Ltd.Legal representative: Lin Zhaoxiong

August 31 2022

5